Doctor Jesper Enander defended his thesis!

Jesper Enander today received his PhD after successfully defending his thesis today. Congratulations Jesper!



Jesper (the tallest) surrounded by his supervisors. To the left the opponent Prof Ulrike Buhlmann being distracted by Prof Jerker Hetta from the examination board.


The examination board: Klaas Wijma, Linköping University, Jerker Hetta and Kalle Lundgren, KI.




It’s done.

Manuel Mattheisen joins our group

Our collaborator Manuel Mattheisen, Associate Professor at Århus University, is now officially affiliated to Karolinska Institutet and our group.  He studied medicine at the University in Bonn and went on to be a research follow at Harvard Medical School before moving to Denmark. We are fortunate to enjoy his deep expertise in genetical methods. Check out his quite spectacular publication list here.





Jesper Enander to defend thesis on May 5th

Jesper is about to defend his thesis titled: “Etiology, prevalence, and development of a novel treatement for body dysmorphic disorder” May 5 at 09.00 in Lecture hall H1, Alfred Nobels Allé 23, Campus Flemingsberg. Do not miss! 

His Opponent will be Professor Ulrike Buhlman, University of Münster.

Examination Board:
Associate Professor Kalle Lundgren, Karolinska Institutet, Department of Molecular Medicine and Surgery

Professor Klaas Wijma, Linköping University, Department of Clinical and Experimental Medicine

Professor Jerker Hetta, Karolinska Institutet, Department of Clinical Neuroscience

Principal Supervisor:
Associate Professor Christian Rück, Karolinska Institutet, Department of Clinical Neuroscience

Professor David Mataix-Cols, Karolinska Institutet, Department of Clinical Neuroscience

Professor Paul Lichtenstein, Karolinska Institutet, Department of Medical Epidemiology and Biostatistics

Associate Professor Brjánn Ljótsson, Karolinska Institutet, Department of Clinical Neuroscience

New meta-analysis in JAMA Psychiatry: Does d-cycoserine add to CBT?

D-cycloserine (DCS) is a partial NMDA agonist that facilitates fear extinction in animals and reduces return of fear when given before  extinction training. Despite several initial trials showing promising results in humans with anxiety disorders larger trials conducted within the past 5 years have produced mixed results. Our large trial in obsessive-compulsive disorder22 found no general effect of DCS but a significant interaction effect between DCS and antidepressant medication in a post hoc analysis;  antidepressants impaired treatment response in patients randomized to DCS but not in patients randomized to placebo.

We collected Individual participant data for 21 of 22 DCS trials, representing 1047 of 1073 eligible participants. When controlling for antidepressant use, participants receiving DCS showed greater improvement from pretreatment to posttreatment (mean difference, −3.62; 95% CI, −0.81 to −6.43; P = .01; d = −0.25) but not from pretreatment to midtreatment (mean difference, −1.66; 95% CI, −1.60 to 4.92; P = .32; d = −0.14) or from pretreatment to follow-up (mean difference, −2.98, 95% CI, −0.03 to 5.99; P = .05; d = −0.19). Only 1 significant moderator emerged: year of publication. Specifically, the more recent the study, the smaller the difference between DCS and placebo for pretreatment to follow-up improvement (b = 4.02; 95% CI, 0.59-7.45; P = .02, d = 0.26).

Conclusion: D-cycloserine is associated with a small augmentation effect on exposure-based therapy. The small size of the effect makes the clinical usefulness of DCS doubtful.


Mataix-Cols D, Fernández de la Cruz L, Monzani B, Rosenfield D, Andersson E, Pérez-Vigil A, Frumento P, de Kleine RA, Difede J, Dunlop BW, Farrell LJ, Geller D, Gerardi M, Guastella AJ, Hofmann SG, Hendriks G, Kushner MG, Lee FS, Lenze EJ, Levinson CA, McConnell H, Otto MW, Plag J, Pollack MH, Ressler KJ, Rodebaugh TL, Rothbaum BO, Scheeringa MS, Siewert-Siegmund A, Smits JAJ, Storch EA, Ströhle A, Tart CD, Tolin DF, van Minnen A, Waters AM, Weems CF, Wilhelm S, Wyka K, Davis M, Rück C, for the DCS Anxiety Consortium. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress DisordersA Systematic Review and Meta-analysisJAMA Psychiatry. Published online January 25, 2017. doi:10.1001/jamapsychiatry.2016.3955